Spark Biomedical just completed a joint venture agreement with Northwell Health and the Feinstein Institute to bring a new novel neuromodulation therapy to market. The new subsidiary, 5 Liters, will take over a decade of preclinical work lead by Kevin Tracey and his team at the Feinstein institute using neurostimulation of the Vagus nerve to activate platelets in order to reduce blood loss and stop bleeding. This novel approach to blood management has applications on the battlefield, in the OR, emergency room, and around the world where expensive hemostatic agents aren't available. 5 Liters will translate the preclinical work to humans and bring this novel, potentially life saving blood management solution to market.